Trans-(-)-ε-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated Protein Kinase (AMPK), and protects cells in models of huntington disease

Journal of Biological Chemistry

Volumn 287, Issue 29, 2012, Pages 24460-24472

  Fu, Jinrong ^a   Jin, Jing ^a   Cichewicz, Robert H ^b   Hageman, Serena A ^b   Ellis, Trevor K ^b   Xiang, Lan ^a   Peng, Qi ^a   Jiang, Mali ^a   Arbez, Nicolas ^a   Hotaling, Katelyn ^a   Ross, Christopher A ^a   Duan, Wenzhen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP-ACTIVATED KINASE; AMP-ACTIVATED PROTEIN KINASE; DEACETYLASE ACTIVITY; ENERGY DEFICIT; ENERGY METABOLISM; HUNTINGTIN; HUNTINGTON DISEASE; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL MEMBRANE POTENTIAL; NATURAL PRODUCTS; NATURALLY OCCURRING; NEURODEGENERATIVE DISORDERS; NEURONAL DYSFUNCTION; NEUROPROTECTION; NEUROPROTECTIVE EFFECTS; NEUROTOXICITY; POLYGLUTAMINE; REACTIVE OXYGEN SPECIES; SIRTUIN;

CHEMICAL ACTIVATION; CYTOLOGY; ENZYME ACTIVITY; NEURODEGENERATIVE DISEASES;

MITOCHONDRIA;

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MUTANT HUNTINGTIN; MUTANT PROTEIN; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE; REACTIVE OXYGEN METABOLITE; SIRTUIN 3; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VINIFERIN;

ANIMAL CELL; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUNTINGTON CHOREA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MOUSE; NEURAL STEM CELL; NEUROBLASTOMA CELL; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BENZOFURANS; CELL LINE, TUMOR; ENERGY METABOLISM; HUNTINGTON DISEASE; MICE; MITOCHONDRIA; RATS; SIRTUIN 3; STILBENES;

EID: 84863794891     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.382226     Document Type: Article

References (58)

1. Harper, P. S. (1996) New genes for old diseases: the molecular basis of myotonic dystrophy and Huntington disease. The Lumleian Lecture 1995. J. R. Coll. Physicians Lond. 30, 221-231
2. The Huntington Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington disease chromosomes. Cell 72, 971-983
3. Mochel, F., and Haller, R. G. (2011) Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121, 493-499
4. Stack, E. C., Matson, W. R., and Ferrante, R. J. (2008) Evidence of oxidant damage in Huntington disease: translational strategies using antioxidants. Ann. N.Y. Acad. Sci. 1147, 79-92
5. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin, J. B. (1986) Replication of the neurochemical characteristics of Huntington disease by quinolinic acid. Nature 321, 168-171 (Pubitemid 16022019)
6. Jin, Y. N., and Johnson, G. V. (2010) The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 42, 199-205
7. Gibson, G. E., Starkov, A., Blass, J. P., Ratan, R. R., and Beal, M. F. (2010) Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death, and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 1802, 122-134
8. Stahl, W. L., and Swanson, P. D. (1974) Biochemical abnormalities in Huntington chorea brains. Neurology 24, 813-819
9. Mann, V. M., Cooper, J. M., Javoy-Agid, F., Agid, Y., Jenner, P., and Schapira, A. H. (1990) Mitochondrial function and parental sex effect in Huntington disease. Lancet 336, 749 (Pubitemid 20309171)
10. Browne, S. E., Bowling, A. C., MacGarvey, U., Baik, M. J., Berger, S. C., Muqit, M. M., Bird, E. D., and Beal, M. F. (1997) Oxidative damage and metabolic dysfunction in Huntington disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (Pubitemid 27212659)
11. Panov, A. V., Gutekunst, C. A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., and Greenamyre, J. T. (2002) Early mitochondrial calcium defects in Huntington disease are a direct effect of polyglutamines. Nat. Neurosci. 5, 731-736 (Pubitemid 34827590)
12. Sawa, A., Wiegand, G. W., Cooper, J., Margolis, R. L., Sharp, A. H., Lawler, J. F., Jr., Greenamyre, J. T., Snyder, S. H., and Ross, C. A. (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 5, 1194-1198 (Pubitemid 29474426)
13. Milakovic, T., and Johnson, G. V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 280, 30773-30782 (Pubitemid 41291807)
14. Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M. A., Hayden, M. R., Masliah, E., Ellisman, M., Rouiller, I., Schwarzenbacher, R., Bossy, B., Perkins, G., and Bossy-Wetzel, E. (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 17, 377-382
15. Schwer, B., North, B. J., Frye, R. A., Ott, M., and Verdin, E. (2002) The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 158, 647-657 (Pubitemid 34920104)
16. Lombard, D. B., Alt, F. W., Cheng, H. L., Bunkenborg, J., Streeper, R. S., Mostoslavsky, R., Kim, J., Yancopoulos, G., Valenzuela, D., Murphy, A., Yang, Y., Chen, Y., Hirschey, M. D., Bronson, R. T., Haigis, M., Guarente, L. P., Farese, R. V., Jr., Weissman, S., Verdin, E., and Schwer, B. (2007) Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807-8814
17. Koehn, F. E., and Carter, G. T. (2005) The evolving role of natural products in drug discovery. Nat. Rev. Drug Disc. 4, 206-220 (Pubitemid 40372555)
18. Feher, M., and Schmidt, J. M. (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci. 43, 218-227
19. Joyner, P. M., and Cichewicz, R. H. (2011) Bringing natural products into the fold: exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases. Nat. Prod. Rep. 28, 26-47
20. Richard, T., Pawlus, A. D., Iglésias, M. L., Pedrot, E., Waffo-Teguo, P., Mérillon, J. M., and Monti, J. P. (2011) Neuroprotective properties of resveratrol and derivatives. Ann. N.Y. Acad. Sci. 1215, 103-108
21. Vang, O., Ahmad, N., Baile, C. A., Baur, J. A., Brown, K., Csiszar, A., Das, D. K., Delmas, D., Gottfried, C., Lin, H. Y., Ma, Q. Y., Mukhopadhyay, P., Nalini, N., Pezzuto, J. M., Richard, T., Shukla, Y., Surh, Y. J., Szekeres, T., Szkudelski, T., Walle, T., and Wu, J. M. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6, e19881
22. Maher, P., Dargusch, R., Bodai, L., Gerard, P. E., Purcell, J. M., and Marsh, J. L. (2011) ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington disease. Hum. Mol. Genet. 20, 261-270
23. Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., and Marsh, J. L. (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington disease. Hum. Mol. Genet. 17, 3767-3775
24. Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., and Néri, C. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37, 349-350
25. Ho, D. J., Calingasan, N. Y., Wille, E., Dumont, M., and Beal, M. F. (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington disease. Exp. Neurol. 225, 74-84
26. Wang, Q., Xu, J., Rottinghaus, G. E., Simonyi, A., Lubahn, D., Sun, G. Y., and Sun, A. Y. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 958, 439-447 (Pubitemid 35441199)
27. Q111 striatal cells. Hum. Mol. Genet. 9, 2799-2809
28. Wang, W., Duan, W., Igarashi, S., Morita, H., Nakamura, M., and Ross, C. A. (2005) Compounds blocking mutant huntingtin toxicity identified using a Huntington disease neuronal cell model. Neurobiol. Dis. 20, 500-508 (Pubitemid 41476276)
29. Brand, M. D., Buckingham, J. A., Esteves, T. C., Green, K., Lambert, A. J., Miwa, S., Murphy, M. P., Pakay, J. L., Talbot, D. A., and Echtay, K. S. (2004) Mitochondrial superoxide and aging: uncoupling-protein activity and superoxide production. Biochem. Soc. Symp. 203-213 (Pubitemid 41185487)
30. RSK and cAMP-dependent protein kinase, but not its farnesylation at Cys-433, is essential for LKB1 to suppress cell growth. J. Biol. Chem. 276, 19469-19482
31. Lin, J., Wu, P. H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C. Y., Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R. M., Cui, L., Manieri, M., Donovan, M. X., Wu, Z., Cooper, M. P., Fan, M. C., Rohas, L. M., Zavacki, A. M., Cinti, S., Shulman, G. I., Lowell, B. B., Krainc, D., and Spiegelman, B. M. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119, 121-135 (Pubitemid 39349325)
32. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., and Krainc, D. (2006) Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59-69 (Pubitemid 44466642)
33. Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., Cui, L., Beyer, R. P., Easley, C. N., Smith, A. C., Krainc, D., Luquet, S., Sweet, I. R., Schwartz, M. W., and La Spada, A. R. (2006) Thermoregulatory and metabolic defects in Huntington disease transgenic mice implicate PGC-1α in Huntington disease neurodegeneration. Cell Metab. 4, 349-362 (Pubitemid 44645069)
34. Cimen, H., Han, M. J., Yang, Y., Tong, Q., Koc, H., and Koc, E. C. (2010) Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 49, 304-311
35. +-dependent deacetylase SIRT3 regulates mitochondrial protein synthesis by deacetylation of the ribosomal protein MRPL10. J. Biol. Chem. 285, 7417-7429
36. Yang, Y., Hubbard, B. P., Sinclair, D. A., and Tong, Q. (2010) Characterization of murine SIRT3 transcript variants and corresponding protein products. J. Cell. Biochem. 111, 1051-1058
37. Kahn, B. B., Alquier, T., Carling, D., and Hardie, D. G. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1, 15-25 (Pubitemid 43960587)
38. Kemp, B. E., Stapleton, D., Campbell, D. J., Chen, Z. P., Murthy, S., Walter, M., Gupta, A., Adams, J. J., Katsis, F., van Denderen, B., Jennings, I. G., Iseli, T., Michell, B. J., and Witters, L. A. (2003) AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31, 162-168 (Pubitemid 36241420)
39. Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., and Hardie, D. G. (2003) Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28
40. Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., and Carling, D. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004-2008 (Pubitemid 37425212)
41. Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., and Cantley, L. C. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 101, 3329-3335 (Pubitemid 38338195)
42. Verdin, E., Hirschey, M. D., Finley, L. W., and Haigis, M. C. (2010) Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem. Sci. 35, 669-675
43. Saunders, L. R., and Verdin, E. (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26, 5489-5504 (Pubitemid 47255930)
44. Kim, S. H., Lu, H. F., and Alano, C. C. (2011) Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One 6, e14731
45. Ahn, B. H., Kim, H. S., Song, S., Lee, I. H., Liu, J., Vassilopoulos, A., Deng, C. X., and Finkel, T. (2008) A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105, 14447-14452
46. Shi, T., Wang, F., Stieren, E., and Tong, Q. (2005) SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280, 13560-13567 (Pubitemid 40517248)
47. Bell, E. L., Emerling, B. M., Ricoult, S. J., and Guarente, L. (2011) SirT3 suppresses hypoxia-inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene 30, 2986-2996
48. Bell, E. L., and Guarente, L. (2011) The SirT3 divining rod points to oxidative stress. Mol. Cell 42, 561-568
49. Tao, R., Karliner, J. S., Simonis, U., Zheng, J., Zhang, J., Honbo, N., and Alano, C. C. (2007) Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in adult rat cardiac myocytes. Biochem. Biophys. Res. Commun. 363, 257-262 (Pubitemid 47484323)
50. Balaban, R. S., Nemoto, S., and Finkel, T. (2005) Mitochondria, oxidants, and aging. Cell 120, 483-495 (Pubitemid 40269763)
51. Arsenijevic, D., Onuma, H., Pecqueur, C., Raimbault, S., Manning, B. S., Miroux, B., Couplan, E., Alves-Guerra, M. C., Goubern, M., Surwit, R., Bouillaud, F., Richard, D., Collins, S., and Ricquier, D. (2000) Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat. Genet. 26, 435-439
52. Schwer, B., Bunkenborg, J., Verdin, R. O., Andersen, J. S., and Verdin, E. (2006) Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc. Natl. Acad. Sci. U.S.A. 103, 10224-10229 (Pubitemid 44051148)
53. + repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 308, 809-813
54. St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., Simon, D. K., Bachoo, R., and Spiegelman, B. M. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408 (Pubitemid 44572377)
55. Uldry, M., Yang, W., St-Pierre, J., Lin, J., Seale, P., and Spiegelman, B. M. (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 3, 333-341
56. Jin, L., Galonek, H., Israelian, K., Choy, W., Morrison, M., Xia, Y., Wang, X., Xu, Y., Yang, Y., Smith, J. J., Hoffmann, E., Carney, D. P., Perni, R. B., Jirousek, M. R., Bemis, J. E., Milne, J. C., Sinclair, D. A., and Westphal, C. H. (2009) Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. Protein Sci. 18, 514-525
57. Hallows, W. C., Lee, S., and Denu, J. M. (2006) Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U.S.A. 103, 10230-10235 (Pubitemid 44051149)
58. Pillai, V. B., Sundaresan, N. R., Kim, G., Gupta, M., Rajamohan, S. B., Pillai, J. B., Samant, S., Ravindra, P. V., Isbatan, A., and Gupta, M. P. (2010) Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 285, 3133-3144